Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Celgene
Celgene
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Fierce Biotech
Fri, 05/3/19 - 10:45 am
Celgene
Bluebird Bio
bb2121
cell therapy
CAR-T
Multiple Myeloma
Seattle life sciences industry has strength in numbers despite uncertainty
Bizjournals
Fri, 05/3/19 - 10:20 am
Seattle
Juno Therapeutics
Celgene
Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming
Motley Fool
Thu, 04/25/19 - 07:14 pm
earnings
Bristol-Myers Squibb
Celgene
M&A
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Fierce Pharma
Tue, 04/23/19 - 05:32 pm
AbbVie
Celgene
JNJ
Merck
Pfizer
Vertex Pharmaceuticals
investors
executive pay
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
CNBC
Sat, 04/13/19 - 12:03 pm
M&A
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
Stat
Fri, 04/12/19 - 11:54 pm
Bristol-Myers Squibb
Celgene
M&A
Big Pharma come together for better drug side effect detection
Pharma Times
Sun, 04/7/19 - 05:18 pm
side effects
adverse events
Pfizer
Roche
Takeda
Eli Lilly
Bristol-Myers Squibb
Gilead Sciences
Alexion
Celgene
International Working Group on Signal Detection and Management in Pharmacovigilance
pharmacovigilance
Celgene and Acceleron Submit BLA for Luspatercept
CP Wire
Fri, 04/5/19 - 11:44 am
Celgene
Acceleron
luspatercept
myelodysplastic syndrome
beta thalassemia
Celgene and Acceleron Submit BLA for Luspatercept
Fri, 04/5/19 - 10:44 am
Celgene
Acceleron
luspatercept
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Endpoints
Thu, 04/4/19 - 11:07 pm
Bristol-Myers Squibb
Celgene
Morgan Stanley
M&A
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
Endpoints
Sun, 03/31/19 - 03:47 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
Giovanni Caforio
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Stat
Fri, 03/29/19 - 10:17 am
Bristol-Myers Squibb
Celgene
M&A
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Wed, 03/27/19 - 10:20 am
Celgene
ozanimod
MS
multiple sclerosis
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
TheStreet.com
Tue, 03/26/19 - 09:44 am
SEC
FTC
M&A
Bristol-Myers Squibb
Celgene
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Fierce Pharma
Thu, 03/21/19 - 12:17 pm
Bristol-Myers Squibb
Celgene
investors
M&A
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Thu, 03/21/19 - 10:01 am
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Endpoints
Tue, 03/19/19 - 10:37 am
Bristol-Myers Squibb
Starboard
Celgene
M&A
UK gets early access to Roche’s breast cancer immunotherapy
Pharmaforum
Sat, 03/16/19 - 12:18 pm
Roche
Tecentriq
Celgene
Abraxane
UK
triple-negative breast cancer
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Motley Fool
Fri, 03/15/19 - 11:55 pm
M&A
Bristol-Myers Squibb
Celgene
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
Yahoo/Reuters
Thu, 03/14/19 - 10:18 am
Celgene
Revlimid
patents
Multiple Myeloma
Alvogen
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »